Kyverna Therapeutics, Inc.
NASDAQ:KYTXBiotechnology
-$0.12 today
- Market cap
- $283.23M
- Beta
- 1.96
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.59
Volume 1.05M
Average 0.94M
KYTX Operating Cash Flow
Cash generated by the company's core business operations during the period.
Kyverna Therapeutics, Inc.NASDAQ: KYTX
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow dips below year-ago levels
Q1 FY2026 operating cash flow of $41.6M (cash outflow) fell 7.4% year over year, behind the +12.5% change in trailing-twelve-month operating cash flow. Sequentially, it rose 24.1% from the prior quarter. Over 3 fiscal years it compounded at +62.1% a year.
Context
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -7.4% toward the trailing-twelve-month pace of +12.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (153.71M) USD
- Year-over-year change
- -34.5%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (153.71M) | -34.5% |
| FY2024 | 2024-12-31 | (114.25M) | -118.0% |
| FY2023 | 2023-12-31 | (52.41M) | -45.1% |
| FY2022 | 2022-12-31 | (36.11M) | -63.0% |
| FY2021 | 2021-12-31 | (22.16M) | — |
Operating Cash Flow vs competitors
How KYTX compares with its peers on the latest reported figures
- KYTX's LTM Mar 2026 operating cash flow of $150.39M is the largest of the 11 companies compared; the peer median is $103.61M.
- Its year-over-year change of +12.5% is the 5th highest of 10, against a peer median of +11.4%.
- Over three fiscal years its annual growth of +62.1% compares with a peer median of +3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $150.39M | +12.5% | +62.1% | — | |
| LTM Mar 2026 | $147.86M | +17.2% | +3.0% | — | |
| LTM Mar 2026 | $142.84M | +50.3% | +41.4% | — | |
| LTM Mar 2026 | $140.5M | -32.5% | -2.3% | 363.1% | |
| LTM Mar 2026 | $133.8M | -23.6% | -4.0% | 431600.0% | |
| LTM Mar 2026 | $109.23M | -44.6% | -12.2% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $97.99M | +11.4% | +21.8% | — |
| LTM Mar 2026 | $92.63M | +105.1% | — | — | |
| LTM Mar 2026 | $65.57M | — | +3.0% | 7115.1% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $57.17M | +46.0% | +40.1% | — |
| LTM Mar 2026 | $26.95M | -18.7% | -14.1% | 5390.8% | |
| Peer median (excluding KYTX) | $103.61M | +11.4% | +3.0% | 6253.0% | |
Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.35M) | (28.89M) | (60.37M) | (127.48M) | (161.31M) |
| Depreciation & Amortization | 586K | 1.05M | 1.71M | 2.13M | 1.8M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.25M | 929K | 2.22M | 8.36M | 10.08M |
| Change in Working Capital | (4.49M) | (10.33M) | 3.42M | 7.86M | (1.08M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 11K | 677K | 4.08M | 736K | 543K |
| Other Working Capital | (4.5M) | (11M) | (659K) | 7.12M | (1.62M) |
| Other Non-Cash Items | 850K | 1.13M | 605K | (5.12M) | (3.21M) |
| Operating Cash Flow | (22.16M) | (36.11M) | (52.41M) | (114.25M) | (153.71M) |
| Capital Expenditures | (1.29M) | (768K) | (621K) | (2.21M) | (5K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 70K |
| Purchases of Investments | 0 | (56.5M) | (54.85M) | (490M) | (364.62M) |
| Sales of Investments | 0 | 43.17M | 46.68M | 323.64M | 398.81M |
| Other Investing Activities | 0 | 0 | 0 | 7.66M | 5.76M |
| Investing Cash Flow | (1.29M) | (14.1M) | (8.79M) | (160.9M) | 40.02M |
| Debt Repayment | (41K) | (249K) | (781K) | (956K) | 23.89M |
| Common Stock Issued | 0 | 0 | 0 | 341.17M | 117.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 30K | 175K | (1M) | (3.1M) | (144K) |
| Financing Cash Flow | 72.52M | 11.88M | 58.12M | 337.11M | 141.17M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 49.08M | (38.33M) | (3.08M) | 61.96M | 27.47M |
| Free Cash Flow | (23.44M) | (36.88M) | (53.03M) | (116.46M) | (153.72M) |
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
Intrinsic Alpha fair value
Locked
Current Price
$4.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.